<code id='A29C473BC6'></code><style id='A29C473BC6'></style>
    • <acronym id='A29C473BC6'></acronym>
      <center id='A29C473BC6'><center id='A29C473BC6'><tfoot id='A29C473BC6'></tfoot></center><abbr id='A29C473BC6'><dir id='A29C473BC6'><tfoot id='A29C473BC6'></tfoot><noframes id='A29C473BC6'>

    • <optgroup id='A29C473BC6'><strike id='A29C473BC6'><sup id='A29C473BC6'></sup></strike><code id='A29C473BC6'></code></optgroup>
        1. <b id='A29C473BC6'><label id='A29C473BC6'><select id='A29C473BC6'><dt id='A29C473BC6'><span id='A29C473BC6'></span></dt></select></label></b><u id='A29C473BC6'></u>
          <i id='A29C473BC6'><strike id='A29C473BC6'><tt id='A29C473BC6'><pre id='A29C473BC6'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:9722
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Why sickle cell disease is getting the first CRISPR treatment
          Why sickle cell disease is getting the first CRISPR treatment

          AdobeNearlyadecadeago,consultantsdeliveredtoRodgerNovakakindofSearscatalogofhumanmalady:200pages,lis

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          'Cuddling' is just what the doctor ordered for a 200

          InthisphotoprovidedbytheAlaskaSeaLifeCenter,WildlifeResponseAnimalCareSpecialistsHalleyWerner,left,a